Soluble markers of inflammation are associated with Framingham scores in HIV-infected patients on suppressive antiretroviral therapy

Journal of Infection

Volumn 63, Issue 5, 2011, Pages 382-390

  Guzmán Fulgencio, María ^a   Medrano, Jose ^b   Rallón, Norma ^b   Echeverria Urabayen, Amaya ^c   Miguel Benito, Jose ^b   Restrepo, Clara ^b   García Álvarez, Mónica ^a   Vispo, Eugenia ^b   San Roman, Jesus ^d   Sánchez Piedra, Carlos ^b   Soriano, Vicente ^b   Resino, Salvador ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^d UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

AIDS; Antiretroviral therapy; Biomarkers; Cardiovascular risk; Chronic immune activation; Endothelial dysfunction; Framingham score

Indexed keywords

BIOLOGICAL MARKER; CD40 LIGAND; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCOSE; INTERCELLULAR ADHESION MOLECULE 1; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SOLUBLE CD40 LIGAND; SOLUBLE ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; SOLUBLE INTERCELLULAR ADHESION MOLECULE 1; SOLUBLE PADGEM PROTEIN; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 1; SOLUBLE VASCULAR CELL ADHESION MOLECULE 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VIRUS RNA;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; FEMALE; FRAMINGHAM RISK SCORE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTENSION; IMMUNOASSAY; INFLAMMATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SEROLOGY; SMOKING; STROKE; SYSTOLIC BLOOD PRESSURE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HIV INFECTIONS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; SPAIN;

EID: 80054078259     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.08.006     Document Type: Article

References (43)

1. Mocroft A., Ledergerber B., Katlama C., Kirk O., Reiss P., D'Arminio Monforte A., et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003 Jul 5, 362(9377):22-29.
2. Lang S., Mary-Krause M., Cotte L., Gilquin J., Partisani M., Simon A., et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 2010 May 15, 24(8):1228-1230.
3. Lewden C., May T., Rosenthal E., Burty C., Bonnet F., Costagliola D., et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008 Aug 15, 48(5):590-598.
4. Lorenz M.W., Stephan C., Harmjanz A., Staszewski S., Buehler A., Bickel M., et al. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis 2008 Feb, 196(2):720-726.
5. Worm S.W., Sabin C., Weber R., Reiss P., El-Sadr W., Dabis F., et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D: A:D) study. J Infect Dis 2010 Feb 1, 201(3):318-330.
6. Aberg J.A. Cardiovascular complications in HIV management: past, present, and future. J Acquir Immune Defic Syndr 2009 Jan 1, 50(1):54-64.
7. Hunt P.W., Martin J.N., Sinclair E., Bredt B., Hagos E., Lampiris H., et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003 May 15, 187(10):1534-1543.
8. Baker J., Quick H., Hullsiek K.H., Tracy R., Duprez D., Henry K., et al. Interleukin-6 and d-dimer levels are associated with vascular dysfunction in patients with untreated HIV infection. HIV Med 2010 Oct 1, 11(9):608-609.
9. Monsuez J.J., Charniot J.C., Escaut L., Teicher E., Wyplosz B., Couzigou C., et al. HIV-associated vascular diseases: structural and functional changes, clinical implications. Int J Cardiol 2009 Apr 17, 133(3):293-306.
10. Ho J.E., Deeks S.G., Hecht F.M., Xie Y., Schnell A., Martin J.N., et al. Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS 2010 Jul 31, 24(12):1897-1905.
11. Hippisley-Cox J., Coupland C., Vinogradova Y., Robson J., Minhas R., Sheikh A., et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008 Jun 28, 336(7659):1475-1482.
12. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998 May 12, 97(18):1837-1847.
13. D'Agostino R.B., Wolf P.A., Belanger A.J., Kannel W.B. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke 1994 Jan, 25(1):40-43.
14. Lekakis J., Ikonomidis I., Palios J., Tsiodras S., Karatzis E., Poulakou G., et al. Association of highly active antiretroviral therapy with increased arterial stiffness in patients infected with human immunodeficiency virus. Am J Hypertens 2009 Aug, 22(8):828-834.
15. Volberding P.A., Murphy R.L., Barbaro G., Barbarini G., Bruno R., Cirelli A., et al. The pavia consensus statement. AIDS 2003 Apr, 17(Suppl 1):S170-S179.
16. Rossi R., Nuzzo A., Guaraldi G., Orlando G., Squillace N., Ligabue G., et al. The role of the Framingham risk score to predict the presence of subclinical coronary atherosclerosis in patients with HIV infection. J Acquir Immune Defic Syndr 2009 Oct 1, 52(2):303-304.
17. Law M.G., Friis-Moller N., El-Sadr W.M., Weber R., Reiss P., D'Arminio Monforte A., et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D: A:D study. HIV Med 2006 May, 7(4):218-230.
18. Edwards-Jackson N., Kerr S., Tieu H., Ananworanich J., Hammer S., Ruxrungtham K., et al. Cardiovascular risk assessment in persons with HIV infection in the developing world: comparing three risk equations in a cohort of HIV-infected Thais. HIV Med 2011 Mar 6.
19. Falcone E.L., Mangili A., Skinner S., Alam A., Polak J.F., Wanke C.A. Framingham risk score and early markers of atherosclerosis in a cohort of adults infected with HIV. Antivir Ther 2011, 16(1):1-8.
20. Tousoulis D., Charakida M., Stefanadis C. Endothelial function and inflammation in coronary artery disease. Heart 2006 Apr, 92(4):441-444.
21. Aukrust P., Muller F., Lien E., Nordoy I., Liabakk N.B., Kvale D., et al. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure. J Infect Dis 1999 Jan, 179(1):74-82.
22. Ross A.C., Rizk N., O'Riordan M.A., Dogra V., El-Bejjani D., Storer N., et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009 Oct 1, 49(7):1119-1127.
23. Baker J.V., Duprez D. Biomarkers and HIV-associated cardiovascular disease. Curr Opin HIV AIDS 2010 Nov, 5(6):511-516.
24. Wolf P.A., D'Agostino R.B., Belanger A.J., Kannel W.B. Probability of stroke: a risk profile from the Framingham study. Stroke 1991 Mar, 22(3):312-318.
25. Francisci D., Giannini S., Baldelli F., Leone M., Belfiori B., Guglielmini G., et al. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. AIDS 2009 Mar 13, 23(5):589-596.
26. Calza L., Manfredi R., Pocaterra D., Chiodo F. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy. J Infect 2008 Jul, 57(1):16-32.
27. Currier J.S. Cardiovascular risk associated with HIV therapy. J Acquir Immune Defic Syndr 2002 Sep 1, 31(Suppl. 1):S16-S23. discussion S4-S5.
28. Blankenberg S., Rupprecht H.J., Bickel C., Peetz D., Hafner G., Tiret L., et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001 Sep 18, 104(12):1336-1342.
29. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000 Mar 23, 342(12):836-843.
30. Zhang L., Peppel K., Sivashanmugam P., Orman E.S., Brian L., Exum S.T., et al. Expression of tumor necrosis factor receptor-1 in arterial wall cells promotes atherosclerosis. Arterioscler Thromb Vasc Biol 2007 May, 27(5):1087-1094.
31. Elkind M.S., Cheng J., Boden-Albala B., Rundek T., Thomas J., Chen H., et al. Tumor necrosis factor receptor levels are associated with carotid atherosclerosis. Stroke 2002 Jan, 33(1):31-37.
32. Pai J.K., Pischon T., Ma J., Manson J.E., Hankinson S.E., Joshipura K., et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004 Dec 16, 351(25):2599-2610.
33. Valgimigli M., Ceconi C., Malagutti P., Merli E., Soukhomovskaia O., Francolini G., et al. Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the cytokine-activation and long-term prognosis in myocardial infarction (C-ALPHA) study. Circulation 2005 Feb 22, 111(7):863-870.
34. Elkind M.S., Luna J.M., Coffey C.S., McClure L.A., Liu K.M., Spitalnik S., et al. The levels of inflammatory markers in the treatment of stroke study (LIMITS): inflammatory biomarkers as risk predictors after lacunar stroke. Int J Stroke 2010 Apr, 5(2):117-125.
35. Alessi M.C., Peiretti F., Morange P., Henry M., Nalbone G., Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997 May, 46(5):860-867.
36. Krause J.C., Toye M.P., Stechenberg B.W., Reiter E.O., Allen H.F. HIV-associated lipodystrophy in children. Pediatr Endocrinol Rev 2005 Sep, 3(1):45-51.
37. He G., Andersen O., Haugaard S.B., Lihn A.S., Pedersen S.B., Madsbad S., et al. Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines. Eur J Clin Invest 2005 Sep, 35(9):583-590.
38. Koppel K., Bratt G., Schulman S., Bylund H., Sandstrom E. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002 Apr 15, 29(5):441-449.
39. Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006 Jul, 6(7):508-519.
40. Hansson G.K. Atherosclerosis - an immune disease: the Anitschkov Lecture 2007. Atherosclerosis 2009 Jan, 202(1):2-10.
41. Meseguer E., Labreuche J., Durdilly C., Echeverria A., Lavallee P.C., Ducrocq G., et al. Prevalence of embolic signals in acute coronary syndromes. Stroke 2010 Feb, 41(2):261-266.
42. Muller O., Hamilos M., Bartunek J., Ulrichts H., Mangiacapra F., Holz J.B., et al. Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol 2010 Feb 1, 105(3):333-338.
43. Polak J.F., Pencina M.J., Pencina K.M., O'Donnell C.J., Wolf P.A., D'Agostino R.B. Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med 2011 Jul 21, 365(3):213-221.